RIGL RIGEL PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1034842 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY171.1%
TTM EPS YoY159.6%
Revenue 3-yr CAGR29.6%
Net income 3-yr CAGR—
Margins
Gross margin89.6%
Operating margin26.3%
Net margin106.6%
FCF margin—
EBITDA margin27.6%
Returns
ROE109.2%
ROA80.2%
ROIC (approx.)28.7%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets15.0%
Debt / equity0.00x
Current ratio2.39x
Interest coverage18.17x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio56.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $80.89M | $78.70M | $58.82M | $69.80M | $69.46M | $101.69M | $53.33M | $57.60M |
| Cost of revenue | $10.78M | $8.53M | $4.61M | $5.96M | $4.75M | $4.50M | $4.41M | $5.79M |
| Gross profit | $70.11M | $70.18M | $54.21M | $63.85M | $64.71M | $97.18M | $48.92M | $51.81M |
| R&D expense | $18.27M | $13.96M | $11.68M | $10.69M | $7.35M | $6.82M | $8.44M | $5.63M |
| SG&A expense | $34.73M | $32.64M | $30.65M | $29.99M | $28.94M | $29.26M | $27.71M | $29.52M |
| Operating income | $17.11M | $23.57M | $11.88M | $23.17M | $28.42M | $61.10M | $12.77M | $16.66M |
| Interest expense | $257,000 | $779,000 | $1.43M | $1.70M | $1.89M | $1.87M | $1.85M | $1.96M |
| Pretax income | $17.41M | $23.59M | $11.66M | $22.71M | $27.62M | $59.98M | $11.51M | $15.22M |
| Income tax | $4.22M | $6.29M | $3.00M | -$245.35M | -$280,000 | $369,000 | $65,000 | $881,000 |
| Net income | $13.19M | $17.29M | $8.65M | $268.06M | $27.90M | $59.61M | $11.45M | $14.34M |
| EBITDA | $18.90M | $24.42M | $12.48M | $23.77M | $29.02M | $61.71M | $13.38M | $17.26M |
| EPS (basic) | 0.70 | 0.93 | 0.47 | — | 1.55 | 3.33 | 0.64 | — |
| EPS (diluted) | 0.65 | 0.88 | 0.44 | — | 1.46 | 3.28 | 0.63 | — |
| Weighted avg. shares (diluted) | 20.44M | 19.57M | 19.69M | — | 19.16M | 18.16M | 18.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.65M | $60.82M | $24.41M | $40.58M | $48.59M | $53.46M | $45.78M | $56.75M |
| Short-term investments | $52.66M | $34.51M | $122.27M | $114.38M | $88.61M | $54.97M | $31.37M | $20.57M |
| Receivables | $56.46M | $56.04M | $49.95M | $51.76M | $45.92M | $39.91M | $41.55M | $41.62M |
| Inventory | $15.80M | $14.37M | $11.65M | $11.51M | $13.30M | $10.42M | $4.66M | $6.00M |
| Current assets | $188.52M | $185.53M | $234.03M | $240.17M | $214.93M | $175.39M | $146.56M | $135.10M |
| PP&E, net | — | — | — | $30,000 | $54,000 | $57,000 | $76,000 | $92,000 |
| Intangibles | $94.59M | $93.88M | $24.16M | $24.75M | $25.34M | $25.92M | $26.51M | $27.10M |
| Total assets | $523.88M | $521.07M | $504.61M | $513.59M | $242.53M | $206.74M | $175.97M | $163.98M |
| Current liabilities | $78.77M | $95.59M | $89.49M | $99.24M | $94.40M | $86.64M | $66.63M | $63.30M |
| Long-term debt | — | — | $45.00M | $52.50M | $60.00M | $60.00M | $60.00M | $60.00M |
| Total debt | — | — | $45.00M | $52.50M | $60.00M | $60.00M | $60.00M | $60.00M |
| Total liabilities | $78.77M | $95.64M | $104.71M | $122.11M | $124.92M | $124.80M | $157.41M | $160.69M |
| Shareholders' equity | $445.11M | $425.42M | $399.90M | $391.48M | $117.61M | $81.93M | $18.57M | $3.29M |
| Net debt | — | — | $20.59M | $11.92M | $11.41M | $6.54M | $14.21M | $3.25M |
| Shares outstanding | — | — | — | 18.31M | — | — | — | 17.71M |
| Cash flow statement | ||||||||
| Operating cash flow | $34.56M | $30.65M | $2.73M | $21.98M | $24.03M | $30.54M | -$893,000 | $14.50M |
| Investing cash flow | -$18.45M | $17.45M | -$7.97M | -$25.36M | -$33.17M | -$23.28M | -$10.55M | -$10.91M |
| Financing cash flow | -$30.29M | -$11.70M | -$10.92M | -$4.57M | $4.27M | $418,000 | $484,000 | $1.47M |
| Depreciation & amortization | $1.79M | $848,000 | $597,000 | $601,000 | $603,000 | $607,000 | $604,000 | $604,000 |
| Stock-based compensation | $4.85M | $6.84M | $3.46M | $2.75M | $3.36M | $3.28M | $3.32M | $2.09M |
| Share buybacks | $1.02M | $511,000 | $3.74M | — | $0 | $0 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.